Lumexa Imaging Announces Second Quarter 2026 Results

RALEIGH, N.C., Aug. 12, 2026 (GLOBE NEWSWIRE) — Lumexa Imaging (Nasdaq: LMRI), one of the nation’s largest providers of outpatient imaging services, today reported results for the second quarter ended June 30, 2026, and updated its full year 2026 outlook.

“During the second quarter, we continued to build on our momentum, delivering strong same-center growth, expanding our mix of advanced imaging and ramping new centers,” said Caitlin Zulla, Chief Executive Officer of Lumexa Imaging. “Some highlights include announcing four new imaging centers year to date and a joint venture with Hospital for Special Surgery (HSS), a globally recognized leader in musculoskeletal health, marking our ninth health system partnership and our second new joint venture in the past twelve months.”

“With a large and growing addressable market and durable demand tailwinds, we believe Lumexa Imaging is well positioned to deliver sustained, profitable growth while expanding access to high-quality, lower-cost imaging for patients, providers, and payors.”

Second Quarter 2026 Highlights:
All comparisons are to the quarter ended June 30, 2025, unless otherwise noted

Consolidated revenues of $264.2 million, an increase of 5.1% from $251.4 million
System-wide revenue growth of 6.0%
Consolidated advanced outpatient volume growth of 6.8% and 6.3% system-wide
Same-center advanced outpatient volume growth of 5.2% consolidated and 4.9% system-wide
Net income of $2.7 million as compared to net loss of $7.2 million
Adjusted EBITDA of $56.4 million as compared to $56.3 million; and a 21.4% Adjusted EBITDA margin as compared to 22.4%
GAAP EPS of $0.03 per share and Adjusted EPS of $0.20 per share

2026 Full Year Outlook:

Lumexa Imaging provided an update on its guidance for the full year ended December 31, 2026.

Reiterating full-year 2026 consolidated revenue guidance of $1.045 billion to $1.097 billion.
Narrowing its full-year 2026 Adjusted EBITDA guidance range to $235 million to $241 million, from its prior range of $234 million to $242 million. The midpoint of $238 million is unchanged. This includes approximately $7 million of public company costs that were not incurred in 2025. (At the midpoint of guidance, the addition of these costs lowers Adjusted EBITDA growth for 2026 versus 2025 from 7% to 4%)
Reiterating guidance for Adjusted EPS of $0.71 to $0.77 per share.

Lumexa Imaging Earnings Conference Call and Webcast
Lumexa Imaging will host a conference call to discuss its second quarter 2026 results, as well as its 2026 outlook, on August 12, 2026 at 5:00 p.m. ET. The call can be accessed via live audio webcast online at ir.lumexaimaging.com. A replay of the webcast will be available at the same link shortly after the completion of the call and will remain available for approximately one year.

Statement Regarding Use of Non-GAAP Financial Measures
This press release uses Adjusted EBITDA and Adjusted EPS, financial measures that are not calculated in accordance with GAAP. We use Adjusted EBITDA and Adjusted EPS, in conjunction with GAAP financial measures, as an integral part of managing our business and to, among other things: (i) monitor and evaluate the performance of our business operations and financial performance; (ii) facilitate internal comparisons of the historical operating performance of our business operations; (iii) review and assess the operating performance of our management team; and (iv) analyze and evaluate financial and strategic planning decisions regarding future operations and annual operating budgets. For a reconciliation of Adjusted EBITDA and Adjusted EPS to the most directly comparable measure calculated in accordance with GAAP, please see below.

We have not reconciled our Adjusted EBITDA or Adjusted EPS guidance to their most directly comparable GAAP measures because we do not and are not able to provide guidance for those GAAP measures due to the uncertainty and potential variability of certain reconciling items, including transaction costs, severance and executive recruiting. Because such items cannot be provided without unreasonable efforts, we are unable to provide the corresponding reconciliations. However, such reconciling items could have a significant impact on our future results.

About Lumexa Imaging

Lumexa Imaging is a nationwide provider of outpatient medical imaging. With over 5,000 team members and greater than 190 outpatient imaging centers, our team conducted approximately 4 million outpatient procedures system-wide in 2025. We are a partner of choice for health systems and radiologists, delivering best-in-class clinical excellence, operations, and state-of-the-art technology across our platform.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this press release may be forward-looking statements. Forward-looking statements generally relate to future events or our future financial or operating performance. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” or “will,” or the negative of these words or other similar terms or expressions that concern our expectations, strategy, plans or intentions. Forward-looking statements in this release include, but are not limited to, statements regarding our expectations regarding our financial position and operating performance, including our guidance for full year 2026 and our assumptions underlying such guidance; our ability to drive future growth and execute on our goals and strategies; and our expectations regarding our product innovation. Our expectations and beliefs regarding these matters may not materialize, and actual results in future periods are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including but not limited to those risk factors identified in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of our Annual Report on Form 10-K for the year ended December 31, 2025 and our later dated Quarterly Reports on Form 10-Q, each as filed with the Securities and Exchange Commission. The forward-looking statements in this press release are based on information available to us as of the date hereof, and we disclaim any obligations to update any forward-looking statements, except as required by law.

Investor Contact
Sue Dooley
Lumexa Imaging
Sue.Dooley@LumexaImaging.com

Media Contact
Melissa Weston
Lumexa Imaging
Melissa.Weston@LumexaImaging.com

Lumexa Imaging Q2 2026 Outpatient Volumes Highlights:

Consolidated	2Q26	2Q25	Increase YoY
Consolidated total procedures	617,722	602,366	2.5%
Consolidated advanced procedures	193,125	180,911	6.8%
% advanced procedures	31.3%	30.0%	123bps
Consolidated same-center advanced volume growth	——	——	5.2%
System-wide
System-wide total procedures	1,022,874	992,118	3.1%
System-wide advanced procedures	382,506	359,948	6.3%
% advanced procedures	37.4%	36.3%	111bps
System-wide same-center advanced volume growth	——	——	4.9%
Note: Advanced Procedures includes MRI and CT modalities. Center count at June 30, 2026 was 192 total, 88 JV and 104 consolidated.

LUMEXA IMAGING HOLDINGS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(IN THOUSANDS, EXCEPT FOR COMMON SHARES)
(Unaudited)
	June 30, 2026			December 31, 2025

ASSETS
Cash and cash equivalents	$	69,705		$	58,828
Accounts receivable		120,637			112,942
Accounts receivable, related party		20,024			18,893
Other receivables		31,552			19,015
Prepaid expenses		14,498			17,582
Total current assets		256,416			227,260
Property and equipment, net of accumulated depreciation		156,062			144,709
Operating lease right-of-use assets		77,033			76,555
Investments in unconsolidated affiliates		423,331			423,191
Intangible assets, net of accumulated amortization		39,722			41,335
Goodwill		807,554			807,554
Other assets		48,654			43,953
TOTAL ASSETS	$	1,808,772		$	1,764,557
LIABILITIES AND EQUITY
Accounts payable	$	27,062		$	44,857
Accrued expenses and other current liabilities		109,167			95,561
Accounts receivable pledging arrangement		1,267			1,599
Current portion of long-term debt		14,330			13,112
Current portion of finance lease liabilities		14,597			11,552
Current portion of operating lease liabilities		11,932			12,513
Total current liabilities		178,355			179,194
Long-term debt, less current maturities		819,753			819,029
Long-term finance lease liabilities, less current maturities		41,177			33,262
Long-term operating lease liabilities, less current maturities		72,296			71,437
Deferred income taxes		43,592			40,772
Other liabilities		38,538			34,740
Total liabilities		1,193,711			1,178,434
COMMITMENTS AND CONTINGENCIES
EQUITY:
Common stock, $0.001 par value, 1,000,000,000 shares authorized, 96,074,976 shares issued and outstanding at June 30, 2026 and 96,109,927 shares issued and outstanding at December 31, 2025		96			96
Additional paid-in-capital		1,241,563			1,217,087
Accumulated deficit		(626,598	)		(631,060	)
Total equity		615,061			586,123
TOTAL LIABILITIES AND EQUITY	$	1,808,772		$	1,764,557

LUMEXA IMAGING HOLDINGS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)
(IN THOUSANDS, EXCEPT FOR SHARE AND PER SHARE DATA)
(Unaudited)

	Three Months Ended June 30,
		2026			2025
REVENUES:
Net patient service revenue	$	203,735		$	198,185
Management fee and other revenue		60,427			53,217
Total revenues		264,162			251,402
OPERATING EXPENSES:
Cost of operations, excluding depreciation and amortization		225,285			212,265
General and administrative expenses		24,397			18,689
Depreciation and amortization		10,083			9,279
(Gain) loss on disposal of property and equipment		(24	)		16
Total operating expenses		259,741			240,249
Equity in earnings of unconsolidated affiliates		18,619			16,527
INCOME FROM OPERATIONS		23,040			27,680
OTHER EXPENSES:
Interest expense		16,222			30,097
Loss on extinguishment and modification of debt		1,053			–
Total other expenses		17,275			30,097
INCOME (LOSS) BEFORE INCOME TAXES		5,765			(2,417	)
Income tax provision		3,020			4,809
NET INCOME (LOSS) AND COMPREHENSIVE INCOME (LOSS)	$	2,745		$	(7,226	)

Weighted average shares outstanding:
Basic		95,983,246			69,526,574
Diluted		96,039,426			69,526,574
Net income (loss) per common share
Basic	$	0.03		$	(0.10	)
Diluted	$	0.03		$	(0.10	)

LUMEXA IMAGING HOLDINGS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)
(IN THOUSANDS, EXCEPT FOR SHARE AND PER SHARE DATA)
(Unaudited)

	Six Months Ended June 30,
	2026		2025
REVENUES:
Net patient service revenue	$	401,053	$	390,483
Management fee and other revenue		115,646		105,920
Total revenues		516,699		496,403
OPERATING EXPENSES:
Cost of operations, excluding depreciation and amortization		443,040		420,662
General and administrative expenses		44,732		36,181
Depreciation and amortization		20,005		18,330
(Gain) loss on disposal of property and equipment		113		(146	)
Total operating expenses		507,890		475,027
Equity in earnings of unconsolidated affiliates		33,643		31,845
INCOME FROM OPERATIONS		42,452		53,221
OTHER EXPENSES:
Interest expense		32,553		59,946
Loss on extinguishment and modification of debt		1,053		–
Total other expenses		33,606		59,946
INCOME (LOSS) BEFORE INCOME TAXES		8,846		(6,725	)
Income tax provision		4,384		8,188
NET INCOME (LOSS) AND COMPREHENSIVE INCOME (LOSS)	$	4,462	$	(14,913	)

Weighted average shares outstanding:
Basic		95,983,240		69,524,980
Diluted		96,011,335		69,524,980
Net income (loss) per common share
Basic	$	0.05	$	(0.21	)
Diluted	$	0.05	$	(0.21	)

LUMEXA IMAGING HOLDINGS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(IN THOUSANDS)
(Unaudited)

	Six Months Ended June 30,
		2026			2025
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss)	$	4,462		$	(14,913	)
Adjustments to reconcile net income (loss) to net cash provided by operating activities
Depreciation and amortization		20,005			18,330
Amortization of operating lease right-of-use assets		7,956			7,424
Amortization of debt issuance costs		1,437			2,871
Amortization of cloud computing implementation costs		760			184
Write-off of debt issuance costs related to extinguishment of debt		46			–
Equity in earnings of unconsolidated affiliates		(33,643	)		(31,845	)
Distributions from investments in unconsolidated affiliates		36,869			32,820
Loss on disposal of property and equipment		113			(146	)
Deferred income taxes		2,820			1,477
Stock-based compensation		25,011			14,720
Other		(535	)		–
Changes in operating assets and liabilities:
Accounts receivable		(7,695	)		(6,870	)
Accounts receivable, related party		(1,131	)		(2,035	)
Capitalized cloud computing implementation costs		(1,647	)		(1,421	)
Other receivables		(12,537	)		(5,410	)
Prepaid expenses		3,034			(7,028	)
Other assets		(4,723	)		(11,311	)
Accounts payable		(18,596	)		1,214
Accrued expenses and other current liabilities		18,085			(11,002	)
Other liabilities		3,798			7,018
Operating lease liabilities		(8,156	)		(5,966	)
Net cash provided by (used in) operating activities		35,733			(11,889	)
CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from sale or disposal of property and equipment		40			713
Acquisition of intangible asset		(600	)		–
Purchases of property and equipment		(14,985	)		(5,602	)
Contributions to investments in unconsolidated affiliates		(3,366	)		–
Net cash used in investing activities		(18,911	)		(4,889	)
CASH FLOWS FROM FINANCING ACTIVITIES:
Payment of third-party debt issuance costs		(154	)		–
Proceeds from long-term debt		9,536			496
Payments of long-term debt		(8,393	)		(7,821	)
Proceeds from revolving line of credit		–			5,000
Payments of finance lease liabilities		(6,602	)		(2,998	)
Capital contributions		–			715
Repayments on accounts receivable pledging arrangement		(332	)		–
Net cash used in financing activities		(5,945	)		(4,608	)
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS		10,877			(21,386	)
CASH AND CASH EQUIVALENTS, beginning of period		58,828			26,131
CASH AND CASH EQUIVALENTS, end of period	$	69,705		$	4,745

LUMEXA IMAGING HOLDINGS, INC. AND SUBSIDIARIES
RECONCILIATION OF GAAP NET INCOME (LOSS) TO ADJUSTED EBITDA
(IN THOUSANDS)
(Unaudited)

	Three Months Ended June 30,
		2026			2025

Net income (loss)	$	2,745		$	(7,226	)
Depreciation and amortization		10,083			9,279
Income tax provision		3,020			4,809
Amortization of basis difference		573			500
Interest expense		16,222			30,097
Stock-based compensation		12,737			8,346
Loss on extinguishment and modification of debt		1,053			–
Loss (gain) on disposal of property and equipment		(24	)		16
Severance and executive recruiting⁽¹⁾		686			803
Strategic initiatives and implementation⁽²⁾		2,659			1,018
Transaction costs⁽³⁾		707			3,875
Litigation and settlements⁽⁴⁾		1,173			–
Other⁽⁵⁾		87			142
Adjustments for equity in earnings
of unconsolidated affiliates⁽⁶⁾		4,724			4,615
Adjusted EBITDA	$	56,445		$	56,274


⁽¹⁾Includes severance and recruiting expenses for executive leadership departures as part of strategic organizational changes.
⁽²⁾Includes third-party consulting, implementation, and integration expenses incurred as part of our strategic transformation and optimization initiatives, specifically related to the deployment of a new technology system and labor model, as well as the development, customization, and integration of a new enterprise resource planning system.
⁽³⁾Includes costs for third party non-recurring IPO costs, buy-side and sell-side due diligence activities to evaluate and execute potential mergers and acquisitions, integrate acquired businesses and one-time employee retention bonuses related to potential mergers and acquisitions.
⁽⁴⁾Consists of litigation and settlement costs for matters not related to core operations.
⁽⁵⁾Consists of other costs related to debt financing, certain de novo start-up costs related to outpatient imaging centers and certain exit costs related to closed outpatient imaging centers.
⁽⁶⁾To adjust for Lumexa Imaging’s proportional share of depreciation and amortization, interest expense and losses/gains on asset disposals, which are included in equity in earnings from unconsolidated affiliates.

LUMEXA IMAGING HOLDINGS, INC. AND SUBSIDIARIES
RECONCILIATION OF GAAP NET INCOME (LOSS) TO ADJUSTED EBITDA
(IN THOUSANDS)
(Unaudited)

	Six Months Ended June 30,
	2026		2025

Net income (loss)	$	4,462	$	(14,913	)
Depreciation and amortization		20,005		18,330
Income tax provision		4,384		8,188
Amortization of basis difference		1,105		1,000
Interest expense		32,553		59,946
Stock-based compensation		25,011		14,720
Loss on extinguishment and modification of debt		1,053		–
Loss (gain) on disposal of property and equipment		113		(146	)
Severance and executive recruiting⁽¹⁾		1,631		2,173
Strategic initiatives and implementation⁽²⁾		3,484		1,886
Transaction costs⁽³⁾		3,289		7,464
Litigation and settlements⁽⁴⁾		1,202		(128	)
Other⁽⁵⁾		82		158
Adjustments for equity in earnings
of unconsolidated affiliates⁽⁶⁾		9,270		8,596
Adjusted EBITDA	$	107,644	$	107,274


⁽¹⁾Includes severance and recruiting expenses for executive leadership departures as part of strategic organizational changes.
⁽²⁾Includes third-party consulting, implementation, and integration expenses incurred as part of our strategic transformation and optimization initiatives, specifically related to the deployment of a new technology system and labor model, as well as the development, customization, and integration of a new enterprise resource planning system.
⁽³⁾Includes costs for third party non-recurring IPO costs, buy-side and sell-side due diligence activities to evaluate and execute potential mergers and acquisitions, integrate acquired businesses and one-time employee retention bonuses related to potential mergers and acquisitions.
⁽⁴⁾Consists of litigation and settlement costs for matters not related to core operations.
⁽⁵⁾Consists of other costs related to debt financing, certain de novo start-up costs related to outpatient imaging centers and certain exit costs related to closed outpatient imaging centers.
⁽⁶⁾To adjust for Lumexa Imaging’s proportional share of depreciation and amortization, interest expense and losses/gains on asset disposals, which are included in equity in earnings from unconsolidated affiliates.

LUMEXA IMAGING HOLDINGS, INC. AND SUBSIDIARIES
SCHEDULE OF ADJUSTED EARNINGS AND EARNINGS PER SHARE
(IN THOUSANDS, EXCEPT PER SHARE DATA)
(Unaudited)

	Three Months Ended June 30,
		2026			2025

Net income (loss)	$	2,745		$	(7,226	)

Stock-based compensation		12,737			8,346
Loss (gain) on disposal of property and equipment		(24	)		16
Loss on extinguishment and modification of debt		1,053			–
Severance and executive recruiting⁽¹⁾		686			803
Strategic initiatives and implementation⁽²⁾		2,659			1,018
Transaction costs⁽³⁾		707			3,875
Litigation and settlements⁽⁴⁾		1,173			–
Other⁽⁵⁾		87			142
Adjustments for equity in earnings
of unconsolidated affiliates⁽⁶⁾		199			81
Total adjustments		19,277			14,281
Tax impact of adjustments⁽⁷⁾		(2,493	)		(1,484	)
Adjusted net income	$	19,529		$	5,571

Weighted average shares outstanding
Basic		95,983,246			69,526,574
Diluted		96,039,426			69,526,574

Adjusted basic net income per share	$	0.20		$	0.08
Adjusted diluted net income per share	$	0.20		$	0.08


⁽¹⁾Includes severance and recruiting expenses for executive leadership departures as part of strategic organizational changes.

⁽²⁾Includes third-party consulting, implementation, and integration expenses incurred as part of our strategic transformation and optimization initiatives, specifically related to the deployment of a new technology system and labor model, as well as the development, customization, and integration of a new enterprise resource planning system.
⁽³⁾Includes costs for third party non-recurring IPO costs, buy-side and sell-side due diligence activities to evaluate and execute potential mergers and acquisitions, integrate acquired businesses and one-time employee retention bonuses related to potential mergers and acquisitions.
⁽⁴⁾Consists of litigation and settlement costs for matters not related to core operations.
⁽⁵⁾Consists of other costs related to debt financing, certain de novo start-up costs related to outpatient imaging centers and certain exit costs related to closed outpatient imaging centers.
⁽⁶⁾To adjust for Lumexa Imaging’s proportional share of losses/gains on asset disposals, which are included in equity in earnings from unconsolidated affiliates.
⁽⁷⁾Tax effected adjustments using blended federal and state effective income tax rate.

LUMEXA IMAGING HOLDINGS, INC. AND SUBSIDIARIES
SCHEDULE OF ADJUSTED EARNINGS AND EARNINGS PER SHARE
(IN THOUSANDS, EXCEPT PER SHARE DATA)
(Unaudited)

	Six Months Ended June 30,
		2026			2025

Net income (loss)	$	4,462		$	(14,913	)

Stock-based compensation		25,011			14,720
Loss (gain) on disposal of property and equipment		113			(146	)
Loss on extinguishment and modification of debt		1,053			–
Severance and executive recruiting⁽¹⁾		1,631			2,173
Strategic initiatives and implementation⁽²⁾		3,484			1,886
Transaction costs⁽³⁾		3,289			7,464
Litigation and settlements⁽⁴⁾		1,202			(128	)
Other⁽⁵⁾		82			158
Adjustments for equity in earnings
of unconsolidated affiliates⁽⁶⁾		595			54
Total adjustments		36,460			26,181
Tax impact of adjustments⁽⁷⁾		(4,461	)		(2,865	)
Adjusted net income	$	36,461		$	8,403

Weighted average shares outstanding
Basic		95,983,240			69,524,980
Diluted		96,011,335			69,524,980

Adjusted basic net income per share	$	0.38		$	0.12
Adjusted diluted net income per share	$	0.38		$	0.12


⁽¹⁾Includes severance and recruiting expenses for executive leadership departures as part of strategic organizational changes.
⁽²⁾Includes third-party consulting, implementation, and integration expenses incurred as part of our strategic transformation and optimization initiatives, specifically related to the deployment of a new technology system and labor model, as well as the development, customization, and integration of a new enterprise resource planning system.
⁽³⁾Includes costs for third party non-recurring IPO costs, buy-side and sell-side due diligence activities to evaluate and execute potential mergers and acquisitions, integrate acquired businesses and one-time employee retention bonuses related to potential mergers and acquisitions.
⁽⁴⁾Consists of litigation and settlement costs for matters not related to core operations.
⁽⁵⁾Consists of other costs related to debt financing, certain de novo start-up costs related to outpatient imaging centers and certain exit costs related to closed outpatient imaging centers.
⁽⁶⁾To adjust for Lumexa Imaging’s proportional share of losses/gains on asset disposals, which are included in equity in earnings from unconsolidated affiliates.
⁽⁷⁾Tax effected adjustments using blended federal and state effective income tax rate.

LUMEXA IMAGING HOLDINGS, INC. AND SUBSIDIARIES
DETAILS OF MANAGEMENT FEE AND OTHER REVENUES
(IN THOUSANDS)
(Unaudited)

	Three Months Ended June 30,
	2026		2025
Components of “management fee and other revenues:”
Fees for managing joint ventured outpatient sites and other third party services	$	26,103	$	20,578
Zero margin pass-throughs of employee, IT and other site level costs paid by Lumexa		34,324		32,639
Total revenues	$	60,427	$	53,217



	Six Months Ended June 30,
	2026		2025
Components of “management fee and other revenues:”
Fees for managing joint ventured outpatient sites and other third party services	$	47,601	$	40,654
Zero margin pass-throughs of employee, IT and other site level costs paid by Lumexa		68,045		65,266
Total revenues	$	115,646	$	105,920

LUMEXA IMAGING HOLDINGS, INC. AND SUBSIDIARIES
SEGMENT REVENUES
(IN THOUSANDS)
(Unaudited)


	THREE MONTHS ENDED JUNE 30, 2026
	OUTPATIENT		PROFESSIONAL		INTERSEGMENT ELIMINATIONS			TOTAL OF REPORTABLE SEGMENTS
Revenue
Net patient service revenue	$	143,747	$	64,280	$	(4,292	)	$	203,735
Management fee and other revenue		52,462		7,965		–			60,427
Total revenues	$	196,209	$	72,245	$	(4,292	)	$	264,162

Lumexa Imaging Announces Second Quarter 2026 Results

Tenax Therapeutics Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Tenax Therapeutics (TENX)

Nasdaq Entrepreneurial Center launches Northwest Arkansas program to help small businesses grow and connect students to paid internships

N-able Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into N-able (NABL)

WSE Investors Have Opportunity to Lead Wise Group plc Securities Fraud Lawsuit Filed by The Rosen Law Firm